A Clinical Investigation of the C2a-Taper™ Acetabular System
Information source: Biomet, Inc.
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Osteoarthritis; Avascular Necrosis; Congenital Hip Dysplasia; Traumatic Arthritis
Intervention: C2a - Taper™ Acetabular System (Device)
Phase: N/A
Status: Recruiting
Sponsored by: Biomet Orthopedics, LLC Overall contact:
Carmen Albany, Phone: 1-800-348-9500, Email: carmen.albany@biomet.com
Summary
The objective of this study is to gather clinical and survivorship information for the
C2a-Taper™ Acetabular System, a ceramic on ceramic hip articulating system.
Clinical Details
Official title: Post Approval Study of the C2a-Taper™ Acetabular System
Study design: Treatment, Open Label, Single Group Assignment
Primary outcome: Harris Hip Score, Radiographic Evaluation
Secondary outcome: Self-assessment forms
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Skeletally mature patients with non-inflammatory degenerative joint disease such as
osteoarthritis, avascular necrosis, congenital hip dysplasia, and traumatic arthritis
Exclusion Criteria:
- Patients with: Osteoporosis, metabolic disorders, osteomalacia, rapid joint
destruction, vascular insufficiency, muscular atrophy, and neuromuscular disease
Locations and Contacts
Carmen Albany, Phone: 1-800-348-9500, Email: carmen.albany@biomet.com
Biomet Orthopedics, LLC, Warsaw, Indiana 46581, United States; Recruiting
Carmen Albany, Phone: 800-348-9500, Email: carmen.albany@biomet.com
Additional Information
Starting date: April 2006
Ending date: April 2022
Last updated: September 25, 2009
|
